Log in

NYSE:AGNAllergan Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$193.02
+193.02 (+∞)
(As of 05/8/2020)
Add
Compare
Today's Range
$191.64
Now: $193.02▼
$193.38
50-Day Range
$184.04
MA: $190.89▼
$193.89
52-Week Range
$114.27
Now: $193.02▼
$202.21
Volume12.44 million shs
Average Volume4.01 million shs
Market Capitalization$63.50 billion
P/E RatioN/A
Dividend Yield1.53%
Beta1.2
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Read More
Allergan logo

Beat the Market (BTM) Rank™

Analyst Opinion: 1.0Community Rank: 3.3Dividend Strength: 1.7Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.52 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSE:AGN
Previous SymbolNYSE:ACT
CUSIP01849010
CIK1578845
Webwww.allergan.com
Phone862-261-7000

Debt

Debt-to-Equity Ratio0.31
Current Ratio1.01
Quick Ratio0.84

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio11.56
P/E Growth1.63

Sales & Book Value

Annual Sales$16.09 billion
Price / Sales3.95
Cash Flow$36.70 per share
Price / Cash Flow5.26
Book Value$177.28 per share
Price / Book1.09

Profitability

EPS (Most Recent Fiscal Year)$17.64
Net Income$-5,271,000,000.00
Net Margins-15.44%
Return on Equity8.46%
Return on Assets5.31%

Miscellaneous

Employees17,400
Outstanding Shares329,002,000
Market Cap$63.50 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.

Allergan (NYSE:AGN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Allergan?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 10 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allergan.

When is Allergan's next earnings date?

Allergan is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Allergan.

How were Allergan's earnings last quarter?

Allergan plc (NYSE:AGN) announced its quarterly earnings data on Monday, February, 10th. The company reported $5.22 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $4.57 by $0.65. The firm earned $4.35 billion during the quarter, compared to analyst estimates of $4.09 billion. Allergan had a negative net margin of 15.44% and a positive return on equity of 8.46%. Allergan's revenue was up 6.6% on a year-over-year basis. During the same period last year, the firm posted $4.29 EPS. View Allergan's earnings history.

How often does Allergan pay dividends? What is the dividend yield for Allergan?

Allergan declared a quarterly dividend on Wednesday, March 18th. Stockholders of record on Thursday, April 16th will be paid a dividend of $0.74 per share on Monday, June 15th. This represents a $2.96 annualized dividend and a yield of 1.53%. The ex-dividend date is Wednesday, April 15th. View Allergan's dividend history.

How will Allergan's stock buyback program work?

Allergan declared that its board has initiated a share repurchase program on Tuesday, January 29th 2019, which permits the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 4.1% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's leadership believes its shares are undervalued.

What price target have analysts set for AGN?

10 analysts have issued 12 month target prices for Allergan's stock. Their forecasts range from $165.00 to $203.00. On average, they expect Allergan's share price to reach $184.89 in the next year. This suggests that the stock has a possible downside of 4.2%. View analysts' price targets for Allergan.

Has Allergan been receiving favorable news coverage?

News stories about AGN stock have been trending negative this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Allergan earned a news sentiment score of -2.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near future. View the latest news about Allergan.

Who are some of Allergan's key competitors?

What other stocks do shareholders of Allergan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Who are Allergan's key executives?

Allergan's management team includes the following people:
  • Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 49)
  • Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 51)
  • Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 64)
  • Mr. Matthew M. Walsh, Exec. VP & CFO (Age 52)
  • Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 51)

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

What is Allergan's stock price today?

One share of AGN stock can currently be purchased for approximately $193.02.

How big of a company is Allergan?

Allergan has a market capitalization of $63.50 billion and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis. Allergan employs 17,400 workers across the globe.

What is Allergan's official website?

The official website for Allergan is www.allergan.com.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.